ARS Pharmaceuticals (SPRY) Revenue (2022 - 2026)

ARS Pharmaceuticals has disclosed Revenue across 5 years of filings, most recently posting $22.7 million for Q1 2026.

• Revenue for Q1 2026 came in at $22.7 million, up 184.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $99.0 million (up 1.92% YoY), and the FY2025 annual result was $84.3 million, down 5.46% from the prior year.
• Revenue came in at $22.7 million for Q1 2026 at ARS Pharmaceuticals, down from $28.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $86.6 million in Q4 2024 to a low of $10000.0 in Q2 2023.
• The 5-year median for Revenue is $2.1 million (2024), against an average of $15.2 million.
• Across the five-year window, Revenue slumped 97.84% in 2023 and jumped 4900.0% in 2024, its largest moves.
• ARS Pharmaceuticals' Revenue stood at $189000.0 in 2022, then tumbled by 94.71% to $10000.0 in 2023, then surged by 865710.0% to $86.6 million in 2024, then plunged by 67.56% to $28.1 million in 2025, then slipped by 19.25% to $22.7 million in 2026.
• The last three Revenue figures came in at $22.7 million (Q1 2026), $28.1 million (Q4 2025), and $32.5 million (Q3 2025), per Business Quant data.